Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes of STS are still limited. As a result, especially in metastatic disease, prognosis is still dismal. The ligands for the activating immunoreceptor NKG2D (NKG2DL) are commonl...

Full description

Bibliographic Details
Main Authors: Ilona Hagelstein, Martina S. Lutz, Moritz Schmidt, Jonas S. Heitmann, Elke Malenke, Yanjun Zhou, Kim L. Clar, Hans-Georg Kopp, Gundram Jung, Helmut R. Salih, Melanie Märklin, Clemens Hinterleitner
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Immunology
Subjects:
sarcoma
NKG2DL
CD3
CD16
fusion protein
mAb
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.653081/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.653081/full

Similar Items